Professor Greg Hannon will investigate the difference between breast cancer cells that are resistant to certain drugs and those that are not. He hopes to find ways to improve treatments so that more people with breast cancer live, and live well.
Dr Helfrid Hochegger is working to understand a new drug target in cancer cells that could be used together with palbociclib to treat triple negative breast cancer. This could provide a new treatment that could help more people with triple negative breast cancer survive.
Dr Rachael Natrajan is working to understand the role of a protein called SF3B1 in oestrogen receptor positive (ER+) breast cancer. She wants to find better ways to treat people whose breast cancer has changes to this protein.
Professor Janet Brown wants to determine if combining an immunotherapy drug avelumab with another drug, radium-233, could make the treatment more effective. She hopes this combination will improve the immune response to secondary breast cancer in the bone and at other sites in the body.
Drugs that help the immune system to detect and destroy cancer cells show promise as a treatment for triple negative breast cancer. Dr Anne Armstrong will be running a trial to see whether giving aspirin alongside one of these drugs makes the treatment more effective at controlling tumours.
Palbociclib is a drug given to people with secondary, oestrogen receptor positive (ER+) breast cancer to help manage their disease. Dr Saskia Wilting is trying to find out who will benefit from taking this drug and why some cancers do not respond to it.